Retrograde Dystrophic Influence of IFN-gamma on Neurons
Project Number5R01NS046649-03
Contact PI/Project LeaderLEIN, PAMELA J
Awardee OrganizationOREGON HEALTH & SCIENCE UNIVERSITY
Description
Abstract Text
DESCRIPTION (provided by applicant): Inflammation is a common etiological factor in the pathogenesis of diverse neurological diseases; however, mechanisms by which inflammation causes neural dysfunction are not well understood. We hypothesize that the pro-inflammatory gamma interferon (IFNgamma) contributes to inflammation-associated neuropathology by acting directly on neurons to induce dendrite retraction and synapse loss. This hypothesis is derived from observations that (1) dendritic atrophy and elevated IFNgamma are coincidental in inflammatory reactions caused by viral infection, trauma or ischemia, in chronic inflammatory or viral diseases such as multiple sclerosis or HIV and in neurodegenerative diseases such as Alzheimer's and Parkinson's disease; and (2) dendritic atrophy has been linked to neural dysfunction. We have recently shown that IFNgamma causes dendritic retraction and synaptic loss in cultured peripheral and central neurons in the absence of adverse effects on cell viability or axons. What is not known is whether IFNgamma elicits the same response in vivo, and if IFNgamma generated by peripheral inflammatory events can initiate dystrophic signals that are propagated back to the soma. The significance of the latter is suggested by observations that many neuropathological inflammatory lesions are largely restricted to white matter or target tissues.
Using neurons of the superior cervical ganglion (SCG) as a model system, we will address the following specific aims: 1) Determine if systemic administration of lFNgamma is sufficient to cause dendrite retraction and synapse loss in vivo; 2) Assess whether IFNgamma signaling from distal axons is sufficient to cause dendritic retraction in neurons grown in compartmented chambers; and 3) Determine if peripheral inflammation causes dendritic retraction in vivo and if IFNgamma is necessary for this effect. Aim 3 will be accomplished by quantifying dendritic arborization in SCG neurons that innervate airways in wildtype, IFNgamma-/- and IFNgamma Ralpha -/- mice following airway infection with Sendai parainfluenza virus. SCG neurons that project to airways will be identified by retrograde labeling with Fast Blue, and dendritic arbors will be visualized using DiI labeling. Major histocompatibility complex-I and nitric oxide synthase expression will be monitored in SCG as biomarkers of exposure to pharmacologically active concentrations of IFNgamma. These studies will provide significant insights regarding the effect of pro-inflammatory cytokines on neural circuitry, and identify a novel mechanism for conveying information about peripheral injury or inflammation to distal brain loci.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
SDS polyacrylamide gel electrophoresisautoradiographyaxonbiological signal transductionbiomarkerdendritesenzyme linked immunosorbent assaygenetically modified animalsinflammationinterferon gammalaboratory mouselaboratory ratmajor histocompatibility complexneuroanatomyneuropathologynitric oxide synthaseparainfluenza virus type 1polymerase chain reactionsomasuperior cervical ganglionsynapseswestern blottings
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
096997515
UEI
NPSNT86JKN51
Project Start Date
16-July-2003
Project End Date
30-April-2007
Budget Start Date
01-May-2004
Budget End Date
30-April-2005
Project Funding Information for 2004
Total Funding
$248,417
Direct Costs
$189,999
Indirect Costs
$58,418
Year
Funding IC
FY Total Cost by IC
2004
National Institute of Neurological Disorders and Stroke
$248,417
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01NS046649-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01NS046649-03
Patents
No Patents information available for 5R01NS046649-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01NS046649-03
Clinical Studies
No Clinical Studies information available for 5R01NS046649-03
News and More
Related News Releases
No news release information available for 5R01NS046649-03
History
No Historical information available for 5R01NS046649-03
Similar Projects
No Similar Projects information available for 5R01NS046649-03